An experimental gene-editing therapy that aims to lower bad cholesterol for the long-term after a single infusion is off to a ...

Sweden: Laroprovstat, the first oral small-molecule PCSK9 inhibitor under clinical development, demonstrated substantial LDL cholesterol–lowering effects in a phase 1 study involving treatment-naive ...

A new pill, enlicitide, reduced LDL (“bad”) cholesterol by about 60% in a large clinical trial, matching the power of injectable therapies. Because it’s taken orally, it could overcome one of the ...

Enlicitide, an oral PCSK9 inhibitor, reduced LDL-C by nearly 60% in adults with or at risk for ASCVD. The medication offers a daily oral alternative to injectable PCSK9 inhibitors, potentially ...

High levels of low-density lipoprotein cholesterol (LDL-C) are a key risk factor for cardiovascular disease, which continues to be one of the leading causes of illness and death globally. LDL-C can ...

Among people with a previous heart attack or stroke, or who are at high risk for one, a daily oral medication may offer an effective alternative to injections of PCSK9 inhibitors to lower low-density ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef Lipids ...